Obsessive-compulsive disorder (OCD) is a psychiatricdisorder characterized by uncontrolled intrusive thoughts, called obsessions,followed by compulsive behaviours that are performed as a response toobsessions. OCD is ranked 10th among the most debilitating disorders by the WHOand is associated with time-consuming symptoms, like distressing repetitivethoughts and compulsive rituals, which can significantly disrupt functionalityand quality of life in a patient (Types of OCD: https://youtu.be/VT-EZ01SqWU?si=Lk3dA3jg7OHFVEnS ). The mostcommon age of onset of OCD is about 18-29. Non-invasive brain stimulation(NIBS) is a promising adjunctive treatment for OCD. NIBS targets specificcortical areas, like the dorsomedial prefrontal cortex (dmPFC), anteriorcingulate cortex (ACC), supplementary motor area (SMA), etc., resulting inbetter treatment outcomes among OCD patients. Deep repetitive TranscranialMagnetic Stimulation (DTMS: https://youtube.com/shorts/5Jzaa8U_nlA?si=fPBNDsIxqobeYWCy )with the H7 coil can stimulate the deeper and broader areas of the corticalnetwork and produce better clinical outcomes. Modulation in neurotransmitterconcentrations, synaptic plasticity via long-term potentiation, and long-termdepression are the classical effects of DTMS. The United States Food and DrugAdministration (US-FDA) approved the use of the H7 coil in 2018 and the CoolD-B80 coil in 2022, using different treatment parameters, for the treatment ofOCD. At ANC the OCD treatment protocol extends over 20 sessions in five days,involving accelerated DTMS regimen. The overall response rate in OCD after 20DTMS sessions is about 65%, meaning 65 out of 100 patients treated will showabout 50% reduction in the severity of their disease. Remission from thedisease is in 47% of the patients (read more: https://pmc.ncbi.nlm.nih.gov/articles/PMC12489419/). Nomajor side effects have been reported by the patients after DTMS treatment.